Beyond Air CEO Steve Lisi Resigns, Robert Goodman Appointed
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy XAIR?
Beyond Air announced that Steve Lisi has resigned as CEO and stepped down from the board of directors, effective March 27 to pursue other opportunities. The board of directors has appointed Robert Goodman, the company's current chief commercial officer and director, as CEO, effective immediately.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XAIR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XAIR
Wall Street analysts forecast XAIR stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.672
Low
6.00
Averages
6.00
High
6.00
Current: 0.672
Low
6.00
Averages
6.00
High
6.00
About XAIR
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Beyond Air CEO Steve Lisi Resigns, Robert Goodman Appointed
- Executive Change: Beyond Air's CEO Steve Lisi resigned effective March 27 after nine years of leadership, during which he oversaw the development and launch of the LungFit PH product, a move that may impact the company's strategic direction and market confidence.
- New CEO Appointment: The company appointed Chief Commercial Officer Robert Goodman as the new CEO immediately, who joined the board in 2025 and has served as Chief Commercial Officer since November 2025, indicating a continuity in commercial strategy and product development moving forward.
- Product Development Impact: Lisi's resignation may introduce uncertainty regarding the market performance of the LungFit PH product, especially following his leadership during its development phase, necessitating a reassessment of the company's product line and market strategy.
- Board Restructuring: This executive change may lead to a strategic restructuring of the board, with Goodman’s commercial background potentially bringing new market opportunities, but also facing integration challenges as the company adapts to new leadership.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
Beyond Air Terminates Agreement with XTL Biopharmaceuticals
- Agreement Termination: Beyond Air has terminated its agreement with XTL Biopharmaceuticals regarding the sale of its majority stake in NeuroNOS, indicating a significant strategic shift for the company.
- Letter of Intent Expiration: The letter of intent signed in January 2026 expired on March 9, 2026, without a definitive agreement, highlighting potential disagreements on transaction terms between the parties.
- Market Reaction: Beyond Air's stock rose 4.40% in premarket trading to $0.8968, suggesting a degree of market optimism regarding the company's future strategic direction despite the termination.
- Executive Change: The recent appointment of Dan Moorhead as CFO may influence the company's financial management and future investment decisions, potentially impacting shareholder confidence moving forward.
See More
Beyond Air Terminates Proposed Transaction with XTL Biopharmaceuticals
- Transaction Termination: Beyond Air announced the termination of its proposed transaction with XTL Biopharmaceuticals, as the letter of intent signed in January 2026 expired on March 9, 2026, indicating challenges in strategic partnerships for the company.
- NeuroNOS Platform Value: Despite the failed transaction, Beyond Air remains committed to maximizing the value of its NeuroNOS platform, with CEO Steve Lisi emphasizing its potential in treating neurological disorders and oncology, reflecting the company's confidence in future developments.
- Core Technology Advancement: Beyond Air will continue to focus on advancing its core nitric oxide platform and LungFit® programs aimed at improving the quality of life for patients with respiratory illnesses, demonstrating the company's ongoing efforts in medical innovation.
- R&D Prospects: NeuroNOS specializes in developing small-molecule therapies to regulate nitric oxide levels in the brain, with preclinical studies showing potential applications in autism and Alzheimer's disease, highlighting the company's leading position in the neuroscience field.
See More
Potential of High-Dose Inhaled Nitric Oxide for Antimicrobial Therapy
- Publication of Findings: Beyond Air has released an independent review article that comprehensively examines the efficacy of high-dose inhaled nitric oxide (iNO), highlighting its broad-spectrum antimicrobial potential in respiratory infections, which could transform existing treatment paradigms and drive innovation in the medical device sector.
- Compilation of Clinical Evidence: The article synthesizes data from 27 studies, demonstrating the safety and efficacy of high-dose iNO in various respiratory infections, including pneumonia and COVID-19, indicating strategic opportunities for the company in developing new therapies.
- Multimodal Mechanisms: High-dose iNO exhibits multiple mechanisms of action, including direct microbial killing, antiviral effects, and inflammation reduction, emphasizing its potential applications in hospital-acquired pneumonia and immunocompromised patients, potentially filling current treatment gaps.
- Future Research Directions: CEO Steve Lisi stated that the publication will serve as a catalyst for new scientific research, accelerating the clinical development of high-dose iNO and further solidifying the company's leadership position in the treatment of respiratory diseases.
See More
Beyond Air CEO Steve Lisi Resigns, Robert Goodman Appointed
- Executive Change: Beyond Air's CEO Steve Lisi resigned effective March 27 after nine years of leadership, during which he oversaw the development and launch of the LungFit PH product, a move that may impact the company's strategic direction and market confidence.
- New CEO Appointment: The company appointed Chief Commercial Officer Robert Goodman as the new CEO immediately, who joined the board in 2025 and has served as Chief Commercial Officer since November 2025, indicating a continuity in commercial strategy and product development moving forward.
- Product Development Impact: Lisi's resignation may introduce uncertainty regarding the market performance of the LungFit PH product, especially following his leadership during its development phase, necessitating a reassessment of the company's product line and market strategy.
- Board Restructuring: This executive change may lead to a strategic restructuring of the board, with Goodman’s commercial background potentially bringing new market opportunities, but also facing integration challenges as the company adapts to new leadership.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
Beyond Air Terminates Agreement with XTL Biopharmaceuticals
- Agreement Termination: Beyond Air has terminated its agreement with XTL Biopharmaceuticals regarding the sale of its majority stake in NeuroNOS, indicating a significant strategic shift for the company.
- Letter of Intent Expiration: The letter of intent signed in January 2026 expired on March 9, 2026, without a definitive agreement, highlighting potential disagreements on transaction terms between the parties.
- Market Reaction: Beyond Air's stock rose 4.40% in premarket trading to $0.8968, suggesting a degree of market optimism regarding the company's future strategic direction despite the termination.
- Executive Change: The recent appointment of Dan Moorhead as CFO may influence the company's financial management and future investment decisions, potentially impacting shareholder confidence moving forward.
See More
Beyond Air Terminates Proposed Transaction with XTL Biopharmaceuticals
- Transaction Termination: Beyond Air announced the termination of its proposed transaction with XTL Biopharmaceuticals, as the letter of intent signed in January 2026 expired on March 9, 2026, indicating challenges in strategic partnerships for the company.
- NeuroNOS Platform Value: Despite the failed transaction, Beyond Air remains committed to maximizing the value of its NeuroNOS platform, with CEO Steve Lisi emphasizing its potential in treating neurological disorders and oncology, reflecting the company's confidence in future developments.
- Core Technology Advancement: Beyond Air will continue to focus on advancing its core nitric oxide platform and LungFit® programs aimed at improving the quality of life for patients with respiratory illnesses, demonstrating the company's ongoing efforts in medical innovation.
- R&D Prospects: NeuroNOS specializes in developing small-molecule therapies to regulate nitric oxide levels in the brain, with preclinical studies showing potential applications in autism and Alzheimer's disease, highlighting the company's leading position in the neuroscience field.
See More
Potential of High-Dose Inhaled Nitric Oxide for Antimicrobial Therapy
- Publication of Findings: Beyond Air has released an independent review article that comprehensively examines the efficacy of high-dose inhaled nitric oxide (iNO), highlighting its broad-spectrum antimicrobial potential in respiratory infections, which could transform existing treatment paradigms and drive innovation in the medical device sector.
- Compilation of Clinical Evidence: The article synthesizes data from 27 studies, demonstrating the safety and efficacy of high-dose iNO in various respiratory infections, including pneumonia and COVID-19, indicating strategic opportunities for the company in developing new therapies.
- Multimodal Mechanisms: High-dose iNO exhibits multiple mechanisms of action, including direct microbial killing, antiviral effects, and inflammation reduction, emphasizing its potential applications in hospital-acquired pneumonia and immunocompromised patients, potentially filling current treatment gaps.
- Future Research Directions: CEO Steve Lisi stated that the publication will serve as a catalyst for new scientific research, accelerating the clinical development of high-dose iNO and further solidifying the company's leadership position in the treatment of respiratory diseases.
See More
